Colfax Corporation
CFXA
New York Stock Exchange177.71
USD
- -
- -
CIK
0001420800
ISIN
US1940142052
CUSIP
194014205
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
41.61
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Matthew L. Trerotola
- Full Time Employees
- 15,400
- Sector
- Industrials
- Industry
- Industrial - Machinery
- Address
- 420 National Business Parkway Annapolis Junction MD United States of America 19808
- IPO Date
- Jan 9, 2019
- CIK
- 0001420800
- Website
- colfaxcorp.com
- Similar Companies
- Business
- Colfax Corporation (NYSE: CFXA), formerly a diversified technology company, completed its strategic transformation in April 2022 by spinning off its Fabrication Technology business as ESAB Corporation and rebranding the remaining Medical Technology operations as Enovis Corporation (NYSE: ENOV), focusing exclusively on medical devices for musculoskeletal care. Enovis develops, manufactures, and distributes high-quality medical devices and related services across the continuum of patient care, including injury prevention, rehabilitation, and reconstructive joint replacement; core product offerings encompass rigid and soft orthopedic bracing, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators for pain management, physical therapy products, and a comprehensive suite of reconstructive joint implants for the hip, knee, shoulder, elbow, foot, ankle, and finger, marketed primarily under the DJO brand to orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals treating degenerative diseases, deformities, traumatic events, and sports-related injuries. Products are sold through independent distributors, healthcare professionals, consumer retail stores, pharmacies, and direct sales channels, with approximately 72% of Medical Technology revenues generated in the United States and the balance primarily in Europe; the company was founded in 1860 as a fluid handling entity, incorporated in its modern form in 1997, and is headquartered in Wilmington, Delaware, with prior addresses in Richmond, Virginia, and Annapolis Junction, Maryland. Key historical expansions included the 2011 acquisition of Charter International (owner of ESAB welding products), the 2018 purchase of DJO Global for $3.15 billion to enter orthopedics, divestitures of fluid handling to Circor International in 2017 and air/gas handling (Howden Turbo) to KPS Capital Partners in 2019 for $1.8 billion, and the 2022 separation of ESAB to streamline into a pure-play medtech strategy, enabling Enovis to pursue focused growth in clinically differentiated solutions for active lifestyles and patient outcomes.
Forget The Covid Apocalypse, Focus On Stocks That Closed Green After Friday's Monster Sell Off
Stanley Black & Decker (NASDAQ:CFXA) Stock Price Up 8.6%
TheStreet Downgrades Stanley Black & Decker (NASDAQ:CFXA) to D+
CFXA Stock Price, Forecast & News (Stanley Black & Decker)